We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Results from a new prespecified analysis of the VYVA (VYtorin Versus Atorvastatin)
trial involving a subgroup of 428 patients with Type 2 diabetes were consistent
with the overall VYVA trial announced earlier this year.
Genta has announced the presentation of clinical data reporting the safety and
activity of Genasense injection, the company's lead anticancer drug, in combination
with rituximab.
Chiron has announced that the Global Alliance for TB Drug Development (TB Alliance)
has initiated Phase I clinical trials for the tuberculosis (TB) drug candidate
PA-824.
Biogen Idec's Phase II clinical study demonstrated that galiximab may be used
in combination with Rituxan and the combination may prolong event-free survival
(EFS) in patients with relapsed or refractory, follicular non-Hodgkin's lymphoma
(NHL) when compared to previous results with Rituxan monotherapy.
Results from three two-year studies show that Exubera, an inhalable, short-acting,
dry powder insulin, provided effective, sustained glycemic control and was well-tolerated
over two years in adults with Type 2 diabetes.
Neurochem's independent safety review board (ISRB) has issued a second recommendation
to continue the company's North American Phase III clinical trial for Alzhemed,
an investigational product candidate for the treatment of Alzheimer's disease.
Cymbalta significantly improved physical, social and emotional functioning,
in addition to overall health, in patients with pain associated with diabetic
peripheral neuropathy (DPNP), compared with those treated with a sugar pill,
according to a pooled analysis of three studies.
Eli Lilly and Company has announced encouraging results from a one-year pilot
study examining the effect of ruboxistaurin mesylate in persons with Type 2
diabetes and kidney disease (also known as "diabetic nephropathy").
Renovis has ended its Phase Ia clinical trial for REN-850, an investigational
small molecule that was being studied for the treatment of multiple sclerosis
(MS).
Theravance has announced that GlaxoSmithKline (GSK) has enrolled the first subjects
in a Phase I clinical study designed to assess the safety, tolerability and
pharmacokinetics of Theravance's investigational, inhaled bronchodilator, GSK656398
(formerly known as TD-5742), for the treatment of chronic obstructive pulmonary
disease (COPD).